• / Free eNewsletters & Magazine
  • / My Account
Home>Glaxo Fined $53 Million in Generic Drug Delay Ruling

Glaxo Fined $53 Million in Generic Drug Delay Ruling

3party Content

Fri, 12 Feb 2016

LONDON—U.K. pharmaceutical company GlaxoSmithKline PLC has been fined £ 37.6 million ($53.7 million) by the U.K.'s Competition and Markets Authority for trying to delay the potential entry of competitors into the U.K. generic-drugs market for antidepressant drug paroxetine. Between 2001 and 2004,
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.